REVLIMID® Evaluated in Combination with Rituximab as a Potential Treatment ... PharmiWeb.com (press release) Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced results from an investigational study evaluating REVLIMID (lenalidomide) in combination with rituximab in patients with treatment-naive chronic lymphocytic ... Celgene Unit Releases Final Phase 2 Data Evaluating REVLIMID and Rituximab (CELG) Final Phase II Data Evaluating REVLIMID and Rituximab in Patients with ... Final Phase II Data Evaluating REVLIMID(R) and Rituximab in Patients with ... |
